Abstract
Objective The Trans Intestinal Cholesterol Excretion (TICE) pathway is a potential therapeutic target to reduce plasma low-density lipoprotein (LDL) cholesterol levels. TICE encompasses the direct excretion of cholesterol by enterocytes into feces. In mice TICE has been shown to be stimulated by a hydrophilic bile acid pool, resulting in increased fecal neutral sterols (FNS) loss and reduced plasma cholesterol levels. We investigated whether treatment with a hydrophilic bile acid – ursodeoxycholic acid (UDCA) - would increase FNS in humans as a proxy for TICE.
Approach and results We performed a randomized double-blind placebo controlled cross-over trial in 20 male participants aged >18 years, with plasma LDL cholesterol levels ≥2.6mmol/L. After a run-in period of ezetimibe 20mg once daily for three weeks, patients were randomized to UDCA 600mg or placebo orally once daily for two weeks. After a three week wash-out, patients underwent the alternate treatment.
At baseline, mean (SD) age, BMI, and plasma LDL cholesterol were 59±11.3 years, 26.4±3.1 kg/m2, and 3.9±0.8 mmol/L, respectively. After UDCA treatment, the plasma bile acid hydrophobicity index was reduced compared to placebo (-115.88% versus +1.85%, p<0.001). The FNS did not change (-5.8% versus +18.8%, p=0.51) and treatment with UDCA increased LDL cholesterol with 0.39 mmol/L (+10.95% versus -3.24%, p=0.002) when compared with placebo.
Conclusion UDCA in combination with ezetimibe increased plasma bile acid hydrophilicity in hypercholesterolaemic subjects, but did not result in increased FNS or decreased LDL cholesterol. This suggests that TICE is not stimulated by an increase in the hydrophilicity of the bile acid pool in humans.
Competing Interest Statement
RFO reports speakers fees from Daiichi Sankyo. ESG has received fees paid to his institution from Amgen, Akcea, Athera, Sanofi?Regeneron, Esperion, Novo Nordisk, Lilly, and Novartis. GKH has received institutional research support from Aegerion, Amgen, AstraZeneca, Eli Lilly, Genzyme, Ionis, Kowa, Pfizer, Regeneron, Roche, Sanofi, and The Medicines Company; speaker's bureau and consulting fees from Amgen, Aegerion, Sanofi, and Regeneron (fees paid to the academic institution). GKH has part?time employment at Novo Nordisk. LFR is co-founder of Lipid Tools BV and reports speakers fees from Ultragenyx, Daiichi Sankyo, and Novartis. The remaining authors declare they have no conflict of interest.
Clinical Trial
NL6932
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Amsterdam UMC gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
